ASIC has wasted no time in the wake of a critical report from the banking royal commission, reporting a 50 percent spike in investigations into financial services companies since the beginning of the month and promising a number of criminal referrals are on the horizon.
Generic drug maker Sandoz must pay $26.34 million to Danish pharmacuetical giant Lundbeck and a subsidiary for infringing the Australian patent behind the blockbuster antidepressant Lexapro, a judge has found.
Gladstone Ports has won access to draft expert reports prepared by Clyde & Co in its $100 million class action against the Queensland government owned organisation, with a judge ruling the documents were not privileged despite their not being used in the case.
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
Investigations into white collar crime and corporate misconduct are expected to increase significantly following the passage of a wide-ranging package of amendments to the country’s whistleblower laws.
A judge has reprimanded CIMIC Group’s preparations to defend a class action against it, saying a late attempt to file critical evidence was a sign something “pretty horrible” had gone on behind the scenes.
Liberal Democrat Senator David Leyonhjelm has lost his challenge to a ruling that denied his request for speedy dismissal of a defamation lawsuit by Greens Senator Sarah Hanson-Young on the grounds of Parliamentary privilege.
A judge has ruled for investors in a class action alleging they sank $12.3 million into a sports trading scam masterminded by convicted conman Peter Foster, saying they were entitled to recover their misappropriated money from the “notorious confidence trickster”.
A judge has recused herself from hearing a lawsuit brought against Norton Rose Fulbright by a former partner, two months after the judge that was initially assigned to the matter dodged a recusal bid by reallocating the case.
Pharmaceutical giant Allergan has streamlined its trade mark case against Self Care Corporation, which makes products marketed as Botox alternatives.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
